N-acetyl-L-cysteine/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases acute kidney injury incidence (any grade)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Compared with non-use of NAC, use of NAC significantly reduced the incidence of CA-AKI by 49% (risk ratio (RR) 0.51, 95% CI 0.31 to 0.82, p<0.01) and all-cause in-hospital mortality by 63% (RR 0.37, 95% CI 0.17 to 0.79, p=0.01).”
Quoted verbatim from Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials.. - Study
- meta-analysis
- Population
- Patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, seven randomised trials pooled
Effect 0.51 risk ratio, 95% CI 0.31 to 0.82
Effect of N-acetylcysteine on prevention of contrast-associated acute kidney injury in patients with STEMI undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomised controlled trials.2020PMID:33067289Permalink
Keep reading
- Everything the graph holds on N-acetyl-L-cysteine
- Every compound studied against Acute kidney injury incidence (any grade)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4Q56F2FN386W774B6HAW1AE